Exscientia
Oxford-based AI-drug-design company combining generative models with automated chemistry to identify drug candidates.
Profile
Exscientia was the first company to put an AI-designed molecule into human trials and listed on Nasdaq before merging with Recursion in 2025 to form one of the largest dedicated AI-pharma companies.
British link
Headquartered in Oxford.
Sectorhealthtech
Stagepublic
FundingPublic/Merged (Recursion)
Employees400+
Founded2012